Research Results: Market Analysis of CRISPR-based Therapies
Information Cluster
Generated Questions & Answers
Who are the leading companies in the CRISPR therapy space?
The leading publicly traded companies identified are CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), and Intellia Therapeutics (NTLA). Several private companies like Beam Therapeutics are also noted as significant players. [Market-Report-Q1.pdf, p. 8]
What are the primary diseases being targeted?
The most advanced clinical trials are focused on monogenic blood disorders such as sickle cell disease and beta-thalassemia. Other key areas include oncology (CAR-T cell therapies), ophthalmology, and certain liver diseases. [Clinical-Trials-Review.docx, p. 3]
What was the largest recent partnership deal mentioned?
Intellia Therapeutics announced a partnership with a major pharmaceutical company worth up to $1.2 billion in potential milestones for the development of in-vivo gene editing therapies for neurological disorders. [Pharma-Deals-2024.txt, line 45]